- Home
- GROW vs NRSN Comparison
GROW vs NRSN Comparison
Compare GROW & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GROW
- NRSN
- Stock Information
- Founded
- GROW 1968
- NRSN 2017
- Country
- GROW United States
- NRSN Israel
- Employees
- GROW N/A
- NRSN N/A
- Industry
- GROW Investment Managers
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- GROW Finance
- NRSN Health Care
- Exchange
- GROW Nasdaq
- NRSN Nasdaq
- Market Cap
- GROW 32.2M
- NRSN 29.8M
- IPO Year
- GROW N/A
- NRSN 2021
- Fundamental
- Price
- GROW $2.57
- NRSN $1.19
- Analyst Decision
- GROW
- NRSN Buy
- Analyst Count
- GROW 0
- NRSN 2
- Target Price
- GROW N/A
- NRSN $14.00
- AVG Volume (30 Days)
- GROW 55.3K
- NRSN 218.5K
- Earning Date
- GROW 11-06-2025
- NRSN 11-03-2025
- Dividend Yield
- GROW 3.50%
- NRSN N/A
- EPS Growth
- GROW N/A
- NRSN N/A
- EPS
- GROW N/A
- NRSN N/A
- Revenue
- GROW $8,452,000.00
- NRSN N/A
- Revenue This Year
- GROW N/A
- NRSN N/A
- Revenue Next Year
- GROW N/A
- NRSN N/A
- P/E Ratio
- GROW N/A
- NRSN N/A
- Revenue Growth
- GROW N/A
- NRSN N/A
- 52 Week Low
- GROW $2.02
- NRSN $0.80
- 52 Week High
- GROW $2.78
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- GROW 48.80
- NRSN 45.34
- Support Level
- GROW $2.55
- NRSN $1.17
- Resistance Level
- GROW $2.72
- NRSN $1.27
- Average True Range (ATR)
- GROW 0.08
- NRSN 0.07
- MACD
- GROW -0.02
- NRSN 0.00
- Stochastic Oscillator
- GROW 11.36
- NRSN 39.04
About GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.